Geron (GERN) Q3 2026 earnings summary

Executive summary

• Q3 RYTELO net product revenue rose 27% YoY to $60.1M; net income was $1.4M versus a net loss of $18.4M in Q3 2025.

• FY 2026 RYTELO revenue guidance remained $220M–$240M, with expectations toward the mid-to-high end; operating expense guidance was reduced to $220M–$230M.

• The gated European launch began with Germany targeted by year-end 2026 and France in 2027; IMpactMF was discontinued after the DMC judged it unlikely to meet its overall-survival endpoint.

Financial highlights

• Q3 total revenue was $60.2M versus $47.2M a year earlier; 9M revenue rose to $169.5M from $135.9M, primarily on higher RYTELO sales volumes.

• Q3 operating income was $5.8M versus an operating loss of $13.9M; 9M operating loss narrowed to $6.5M from $43.0M.

• Q3 R&D expense was $12.7M versus $21.1M and SG&A was $35.7M versus $39.0M; declines largely reflected lower headcount after the 2025 restructuring.

• Q3 COGS was $6.1M, including $4.8M of noncash inventory write-offs; 9M COGS was $17.0M, including $11.2M of noncash write-offs.

Outlook and guidance

• FY 2026 RYTELO net product revenue guidance remained $220M–$240M, with expectations toward the mid-to-high end of the range.

• FY 2026 total operating expense guidance was lowered to $220M–$230M from $230M–$240M.

• Q4 gross-to-net adjustments are expected in the low-to-mid-20% range; 2027 expenses are expected to rise as European operations mature and post-marketing trials continue.

• Cash resources and anticipated RYTELO sales are expected to fund projected operating requirements for the foreseeable future, subject to sales and cost assumptions.